292 related articles for article (PubMed ID: 34096652)
1. Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
Seger AD; Farrher E; Doppler CEJ; Gogishvili A; Worthoff WA; Filss CP; Barbe MT; Holtbernd F; Shah NJ; Fink GR; Sommerauer M
Mov Disord; 2021 Sep; 36(9):2187-2192. PubMed ID: 34096652
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
Kremer T; Taylor KI; Siebourg-Polster J; Gerken T; Staempfli A; Czech C; Dukart J; Galasko D; Foroud T; Chahine LM; Coffey CS; Simuni T; Weintraub D; Seibyl J; Poston KL; Toga AW; Tanner CM; Marek K; Hutten SJ; Dziadek S; Trenkwalder C; Pagano G; Mollenhauer B
Mov Disord; 2021 Aug; 36(8):1972-1978. PubMed ID: 33942926
[TBL] [Abstract][Full Text] [Related]
3. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions.
Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS
Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448
[TBL] [Abstract][Full Text] [Related]
4. Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study.
Meng Y; Pople CB; Huang Y; Jones RM; Ottoy J; Goubran M; Oliveira LM; Davidson B; Lawrence LSP; Lau AZ; Bethune A; Maralani P; Abrahao A; Hamani C; Hynynen K; Kalia SK; Lipsman N; Kalia LV
Mov Disord; 2022 Oct; 37(10):2134-2139. PubMed ID: 36089809
[TBL] [Abstract][Full Text] [Related]
5. GABAergic changes in the thalamocortical circuit in Parkinson's disease.
van Nuland AJM; den Ouden HEM; Zach H; Dirkx MFM; van Asten JJA; Scheenen TWJ; Toni I; Cools R; Helmich RC
Hum Brain Mapp; 2020 Mar; 41(4):1017-1029. PubMed ID: 31721369
[TBL] [Abstract][Full Text] [Related]
6. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
[TBL] [Abstract][Full Text] [Related]
7. Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study.
Song Y; Gong T; Xiang Y; Mikkelsen M; Wang G; Edden RAE
J Neurol Sci; 2021 Mar; 422():117309. PubMed ID: 33548666
[TBL] [Abstract][Full Text] [Related]
8. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
[TBL] [Abstract][Full Text] [Related]
9. Putaminal dopamine modulates movement motivation in Parkinson's disease.
Banwinkler M; Dzialas V; Rigoux L; Asendorf AL; Theis H; Giehl K; Tittgemeyer M; Hoenig MC; van Eimeren T
Brain; 2024 Jun; ():. PubMed ID: 38941444
[TBL] [Abstract][Full Text] [Related]
10. Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease.
Pesch B; Casjens S; Woitalla D; Dharmadhikari S; Edmondson DA; Zella MAS; Lehnert M; Lotz A; Herrmann L; Muhlack S; Kraus P; Yeh CL; Glaubitz B; Schmidt-Wilcke T; Gold R; van Thriel C; Brüning T; Tönges L; Dydak U
Cells; 2019 Jan; 8(2):. PubMed ID: 30699914
[TBL] [Abstract][Full Text] [Related]
11. Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels.
Te Vruchte D; Sturchio A; Priestman DA; Tsitsi P; Hertz E; Andréasson M; Markaki I; Wallom KL; Platt F; Svenningsson P
Mov Disord; 2022 Oct; 37(10):2129-2134. PubMed ID: 35876461
[TBL] [Abstract][Full Text] [Related]
12. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease.
Scherfler C; Seppi K; Mair KJ; Donnemiller E; Virgolini I; Wenning GK; Poewe W
Brain; 2012 Nov; 135(Pt 11):3348-54. PubMed ID: 23043142
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory motor dysfunction in parkinson's disease subtypes.
Gong T; Xiang Y; Saleh MG; Gao F; Chen W; Edden RAE; Wang G
J Magn Reson Imaging; 2018 Jun; 47(6):1610-1615. PubMed ID: 28960581
[TBL] [Abstract][Full Text] [Related]
14. Upper brainstem GABA levels in Parkinson's disease.
Song Y; Gong T; Saleh MG; Mikkelsen M; Wang G; Edden RAE
MAGMA; 2021 Oct; 34(5):689-696. PubMed ID: 33745095
[TBL] [Abstract][Full Text] [Related]
15. Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
van den Heuvel L; Evers LJW; Meinders MJ; Post B; Stiggelbout AM; Heskes TM; Bloem BR; Krijthe JH
Mov Disord; 2021 Feb; 36(2):407-414. PubMed ID: 33107639
[TBL] [Abstract][Full Text] [Related]
16. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
[TBL] [Abstract][Full Text] [Related]
17. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.
Gilat M; Bell PT; Ehgoetz Martens KA; Georgiades MJ; Hall JM; Walton CC; Lewis SJG; Shine JM
Neuroimage; 2017 May; 152():207-220. PubMed ID: 28263926
[TBL] [Abstract][Full Text] [Related]
18. Re-emergent tremor in Parkinson's disease: the effect of dopaminergic treatment.
Belvisi D; Conte A; Cutrona C; Costanzo M; Ferrazzano G; Fabbrini G; Berardelli A
Eur J Neurol; 2018 Jun; 25(6):799-804. PubMed ID: 29512863
[TBL] [Abstract][Full Text] [Related]
19. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
[TBL] [Abstract][Full Text] [Related]
20. Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD; Ray-Chaudhury A; Kleiner DE; Ehrlich DJ; Scott G; Edwards NA; Goldstein DS; Hammoud DA; Hadaczek P; Van Laar VS; Graff SA; Herscovitch P; Lungu C; Hallett M; Lonser RR; Zaghloul KA; Bankiewicz KS
Mov Disord; 2024 May; ():. PubMed ID: 38718138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
